175 related articles for article (PubMed ID: 29877246)
1. [Chronic graft-versus-host disease: diagnosis and treatment].
Inamoto Y
Rinsho Ketsueki; 2018; 59(5):549-556. PubMed ID: 29877246
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
3. [Evolving treatment strategies for chronic graft-versus-host disease].
Inamoto Y
Rinsho Ketsueki; 2022; 63(5):433-439. PubMed ID: 35662168
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
5. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Toubai T; Hosokawa Y
Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
[TBL] [Abstract][Full Text] [Related]
7. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Chronic Graft versus Host Disease -Review].
Wang FY; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):286-290. PubMed ID: 28245418
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Nakasone H; Sahaf B; Miklos DB
Int J Hematol; 2015 May; 101(5):438-51. PubMed ID: 25812839
[TBL] [Abstract][Full Text] [Related]
11. Expansion of circulating extrafollicular helper T-like cells in patients with chronic graft-versus-host disease.
Jin H; Yang K; Zhang H; Chen Y; Qi H; Fan Z; Huang F; Xuan L; Lin R; Zhao K; Liu Q
J Autoimmun; 2019 Jun; 100():95-104. PubMed ID: 30878167
[TBL] [Abstract][Full Text] [Related]
12. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
[TBL] [Abstract][Full Text] [Related]
13. [Association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Wang HT; Zhao XY; Zhao XS; Han TT; Lv M; Chang YJ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):679-84. PubMed ID: 23978019
[TBL] [Abstract][Full Text] [Related]
14. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.
Greinix HT; Kuzmina Z; Weigl R; Körmoczi U; Rottal A; Wolff D; Kralj M; Kalhs P; Mitterbauer M; Rabitsch W; Edinger M; Holler E; Pickl WF
Biol Blood Marrow Transplant; 2015 Feb; 21(2):250-8. PubMed ID: 25460358
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
[TBL] [Abstract][Full Text] [Related]
16. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
17. Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease.
Wang B; Hu Y; Liu L; Hu K; Tie R; He Y; Fu S; Zhu N; Luo Y; Yu X; Huang H
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1020-8. PubMed ID: 25708216
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
[TBL] [Abstract][Full Text] [Related]
19. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease.
Yehudai-Ofir D; Henig I; Zuckerman T
Autoimmun Rev; 2020 Apr; 19(4):102493. PubMed ID: 32062034
[TBL] [Abstract][Full Text] [Related]
20. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
